Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production

Circulation

Volumn 105, Issue 17, 2002, Pages 2083-2091

  Wassmann, Sven ^a   Laufs, Ulrich ^a   Stamenkovic, Djordje ^a   Linz, Wolfgang ^c   Stasch, Johannes Peter ^d   Ahlbory, Katja ^a   Rösen, Renate ^b   Böhm, Michael ^a   Nickenig, Georg ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^d BAYER AG   (Germany)

Author keywords

Endothelial dysfunction; Estrogen; Hypertension; Nitric oxide; Reactive oxygen species

Indexed keywords

ANGIOTENSIN; ESTROGEN; ESTROGEN RECEPTOR; NITRIC OXIDE; PHENYLEPHRINE; RALOXIFENE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BIOAVAILABILITY; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; CELLS, CULTURED; CULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; HYPERTENSION; MALE; MUSCLE, SMOOTH, VASCULAR; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RALOXIFENE; RATS; RATS, INBRED SHR; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VASOCONSTRICTION; VASODILATION;

EID: 0037197781     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000014618.91633.67     Document Type: Article

References (45)

1. Cardiovascular health and disease in women
2. Menopause and the risk of coronary heart disease in women
3. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women
4. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women
5. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women: The atherosclerosis risk in communities study investigators
6. The protective effects of estrogen on the cardiovascular system
7. Hormone replacement therapy and osteoporosis
8. Hormone replacement therapy for prevention and treatment of osteoporosis
9. Hormone replacement therapy
10. The benefits and risks of hormone replacement therapy: An epidemiologic overview
11. Selective estrogen receptor modulators: A look ahead
12. Selective estrogen receptor modulators
13. Raloxifene, a new selective estrogen receptor modulator
14. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism
15. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
16. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
17. Endothelial function and oxidant stress
18. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress
19. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system
20. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension
21. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors
22. 1 receptor expression and rac 1 GTPase
23. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species
24. Coronary risk factors, endothelial function, and atherosclerosis: A review
25. Hormone replacement therapy and cardiovascular disease
26. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro
27. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium
28. 2+ mobilization
29. Hypocholesterolemic activity of raloxifene (LY139481): Pharmacological characterization of a selective estrogen receptor modulator
30. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits
31. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)
32. Coronary and uterine vascular responses to raloxifene in the sheep
33. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
34. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone
35. NADPH oxidase: An update
36. NAD(P)H oxidase: Role in cardiovascular biology and disease
37. Cell transformation by the superoxide-generating oxidase mox1
38. Novel gp91phox homologues in vascular smooth muscle cells: Nox1 mediates angiotensin H-induced superoxide formation and redox-sensitive signaling pathways
39. Rac1 disrupts p67phox/p40phox binding: A novel role for rac in NADPH oxidase activation
40. Mechanisms of NADPH oxidase activation in human neutrophils: P67phox is required for the translocation of racl but not rac2 from cytosol to the membranes
41. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats
42. Superoxide anion production is increased in a model of genetic hypertension: Role of the endothelium
43. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats
44. Superoxide excess in hypertension and aging: A common cause of endothelial dysfunction
45. Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats